Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
CLBE-CALBATECH INC bio-tech
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by QuestSolver: [QB] CalbaTech is focused on providing products and platforms to the life sciences research market, both for biotech and pharmaceutical companies, as well as academic and government institutions. CalbaTech is pursuing a classic "roll-up" strategy of growth by acquisition. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that CalbaTech believes will contribute breakthrough innovation in areas of biological discovery. Currently, [b]CalbaTech contains four wholly owned subsidiaries, Molecula Research Laboratories, LLC. ("Molecula"), KD Medical, Inc. ("KD"), LifeStem, Inc. ("LifeStem") and Molecularware, Inc. ("Molecularware")[/b] that serve niche markets in the life sciences research market. Molecula and Molecularware were acquired by CTI in 2003, KD was acquired in November 2004, and LifeStem was incorporated in September 2004 to pursue opportunities in the rapidly expanding stem cell market. In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency. CTI's business strategy is establish shareholder value by creating a significant new provider of research reagents, equipment and services to the life sciences market, primarily through acquisition of life science companies that share two or more of the following attributes: 1) They will be generating revenues; 2)[b]They will be profitable;[/b] and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products. [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2